Application Data
(Published customer image:Mouse anti Porcine CD11R3 antibody, clone 2F4/11 employed in the measurement of CD11R3 expression as a measure of neutrophil activation in a porcine model of metabolic syndrome by flow cytometry.Image caption:Systemic neutrophil activation can be evaluated by acute changes in CD11R3 expression and the percent circulating neutrophil population that is resistant to apoptosis in vitro. CD11R3 expression is increased acutely with neutrophil activation. With SCD exposure, CD11R3 expression decreased (a, n-6*, p=0.033). During the activated state neutrophil apoptosis is delayed. In these MetS animals, prior to SCD treatment, 34% of neutrophils are activated (resistant to apoptosis), while in healthy animals, less than 10% of circulating neutrophils are expected to be resistant to apoptosis. Analysis of apoptosis, before and after treatments, showed SCD Rx to move the neutrophil population to a less activated state, thus shifting toward naïve percentages of neutrophils resistant to apoptosis (b, n=9, p=0.023). For CD11R3 expression, only 2 of the 3 SCD Rx courses with three 6-hour treatments each were included in the analysis (n=6) due to an unanticipated analytic procedural complication.From: Angela J. Westover, Kimberly A. Johnston, Deborah A. Buffington, and H. David Humes,“An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome,”)
Mouse anti-Pig CD11R3 Monoclonal Antibody | anti-CD11R3 antibody
MOUSE ANTI PIG CD11R3:RPE
ALEXA FLUOR 647, FITC, Purified, RPE
Phosphate buffered saline
0.09% sodium azide (NaN3)
1% bovine serum albumin
5% sucrose
Application Data
(Published customer image:Mouse anti Porcine CD11R3 antibody, clone 2F4/11 employed in the measurement of CD11R3 expression as a measure of neutrophil activation in a porcine model of metabolic syndrome by flow cytometry.Image caption:Systemic neutrophil activation can be evaluated by acute changes in CD11R3 expression and the percent circulating neutrophil population that is resistant to apoptosis in vitro. CD11R3 expression is increased acutely with neutrophil activation. With SCD exposure, CD11R3 expression decreased (a, n-6*, p=0.033). During the activated state neutrophil apoptosis is delayed. In these MetS animals, prior to SCD treatment, 34% of neutrophils are activated (resistant to apoptosis), while in healthy animals, less than 10% of circulating neutrophils are expected to be resistant to apoptosis. Analysis of apoptosis, before and after treatments, showed SCD Rx to move the neutrophil population to a less activated state, thus shifting toward naïve percentages of neutrophils resistant to apoptosis (b, n=9, p=0.023). For CD11R3 expression, only 2 of the 3 SCD Rx courses with three 6-hour treatments each were included in the analysis (n=6) due to an unanticipated analytic procedural complication.From: Angela J. Westover, Kimberly A. Johnston, Deborah A. Buffington, and H. David Humes,“An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome,”)
Application Data
(Published customer image:Mouse anti Porcine CD11R3 antibody, clone 2F4/11 employed in the measurement of CD11R3 expression as a measure of neutrophil activation in a porcine model of metabolic syndrome by flow cytometry.Image caption:Systemic neutrophil activation can be evaluated by acute changes in CD11R3 expression and the percent circulating neutrophil population that is resistant to apoptosis in vitro. CD11R3 expression is increased acutely with neutrophil activation. With SCD exposure, CD11R3 expression decreased (a, n-6*, p=0.033). During the activated state neutrophil apoptosis is delayed. In these MetS animals, prior to SCD treatment, 34% of neutrophils are activated (resistant to apoptosis), while in healthy animals, less than 10% of circulating neutrophils are expected to be resistant to apoptosis. Analysis of apoptosis, before and after treatments, showed SCD Rx to move the neutrophil population to a less activated state, thus shifting toward naïve percentages of neutrophils resistant to apoptosis (b, n=9, p=0.023). For CD11R3 expression, only 2 of the 3 SCD Rx courses with three 6-hour treatments each were included in the analysis (n=6) due to an unanticipated analytic procedural complication.From: Angela J. Westover, Kimberly A. Johnston, Deborah A. Buffington, and H. David Humes,“An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome,”)
Application Data
(Figure A. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse IgG1 isotype control . Figure B. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse anti porcine CD11R3 . All experiments performed on red cell lysed porcine blood gated on mononuclear cells.)
Application Data
(Figure A. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse IgG1 isotype control . Figure B. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse anti porcine CD11R3 . All experiments performed on red cell lysed porcine blood gated on mononuclear cells.)
Application Data
(Figure A. FITC conjugated mouse anti porcine CD11R3 and APC conjugated mouse IgG1 isotype control . Figure B. FITC conjugated mouse anti porcine CD11R3 and APC conjugated mouse anti porcine CD31. All experiments performed on red cell lysed porcine blood gated on mononuclear cells.)
Application Data
(Figure A. FITC conjugated mouse anti porcine CD11R3 and APC conjugated mouse IgG1 isotype control . Figure B. FITC conjugated mouse anti porcine CD11R3 and APC conjugated mouse anti porcine CD31. All experiments performed on red cell lysed porcine blood gated on mononuclear cells.)
Application Data
(Figure A. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse IgG1 isotype control . Figure B. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse anti porcine CD11R3 . All experiments performed on red cell lysed porcine blood gated on lymphocytes. Data acquired on the ZE5 Cell Analyzer.)
Application Data
(Figure A. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse IgG1 isotype control . Figure B. APC conjugated mouse anti porcine CD31 and FITC conjugated mouse anti porcine CD11R3 . All experiments performed on red cell lysed porcine blood gated on lymphocytes. Data acquired on the ZE5 Cell Analyzer.)
Similar Products
Product Notes
The CD11R3 (Catalog #AAA50480) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The MOUSE ANTI PIG CD11R3:RPE reacts with Pig and may cross-react with other species as described in the data sheet. AAA Biotech's CD11R3 can be used in a range of immunoassay formats including, but not limited to, FCM/FACS (Flow Cytometry). Researchers should empirically determine the suitability of the CD11R3 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CD11R3, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.